Lactobacillus and bacillus based direct fed microbial treatment for poultry and method of use

Patent metadata

Field	Value
Publication number	US-11298383-B2
Application number	US-201715601656-A
Country	US
Kind code	B2
Filing date	May 22, 2017
Priority date	May 20, 2016
Publication date	Apr 12, 2022
Grant date	Apr 12, 2022

Abstract

This disclosure relates generally to a microbial treatment for poultry. More particularly, the disclosure relates to a direct fed microbial composition including one or more lactic acid bacteria strains in combination with one or more Bacillus bacteria strains configured to inhibit gastrointestinal pathogens in a bird. A method of use is also disclosed herein.

First claim

We claim:

1. A method of improving bird performance, comprising:
introducing into the gastrointestinal tract of one or more birds on the day-of hatch an effective amount of the direct fed microbial composition comprising at least one Bacillus strain and at least one Lactobacillus strain;
wherein the at least one Lactobacillus strain is chosen from at least one of strains Lactobacillus plantarum Lp-115 and Lactobacillus salivarius Ls-33; and the at least one Bacillus strain is chosen from at least one of strains Bacillus subtilis 747 deposited as NRRL B-67257, Bacillus subtilis 967, Bacillus subtilis 1104 deposited as NRRL B-67258, Bacillus subtilis 1145, Bacillus subtilis 1541 deposited as NRRL B-67260, Bacillus subtilis 1781 deposited as NRRL B-67259, Bacillus subtilis 1999 deposited as NRRL B-67318, and Bacillus subtilis 2018 deposited as NRRL B-67261;
wherein the ratio of the at least one Lactobacillus strain to the at least one Bacillus strain in said direct fed microbial composition is at least about 4:1;
wherein the effective amount of said direct fed microbial composition comprises a concentration of the isolated Bacillus strain of between about 2.5×10 7 CFU/bird and about 1.0×10 9 CFU/bird and a concentration of the isolated Lactobacillus strain of between about 2.5×10 7 CFU/bird and about 1.0×10 9 CFU/bird;
and wherein the introduction of the direct fed microbial composition provides at least one benefit chosen from:
inhibiting a pathogen chosen from at least one of Escherichia coli, Clostridium perfringens and Enterobacteriaceae in the one or more birds;
decreasing a mortality rate of the one or more birds;
improving the coefficient of variation of weight of the one or more birds;
reducing the occurrence of necrotic enteritis in the one or more birds;
reducing the occurrence of colibacillosis in the one or more birds; and
modulating immune responses of inflammatory cytokines in gastrointestinal epithelial cells in the one or more birds.

2. The method of claim 1 , wherein the at least one Lactobacillus strain is Lactobacillus salivarius Ls-33, and the administration of the direct fed microbial composition provides the benefit of amelioration of the gastrointestinal inflammatory cytokine response associated with a gram negative bacterial infection in the gastrointestinal tract of the one or more birds.

3. The method of claim 1 , wherein the administration of the direct fed microbial composition provides the benefit of eliciting an immunomodulatory effect in gastrointestinal epithelial cells to control inflammatory responses associated with the stress of enteric pathogenic challenges in the one or more birds.

4. The method of claim 1 , wherein the introduction step includes:
wetting the direct fed microbial composition;
spraying the wetted composition onto an outer surface of the one or more birds to form droplets; and
inducing a bird to ingest one or more of the droplets from the outer surface of a different bird.

5. The method of claim 4 , where in the wetted composition includes a color attractant configured to induce ingestion of the droplets by said birds.

6. The method of claim 1 , wherein the ratio of the at least one Lactobacillus strain to the at least one Bacillus strain in said direct fed microbial composition is at least about 9.1.

Assignees

• Church & Dwight Co Inc

Inventors

• Rehberger Thomas
• Hutchison Evan
• Smith Alexandra

Classifications

• A23K10/18

  of live microorganisms · CPC title

• A61K35/742

  Spore-forming bacteria, e.g. Bacillus coagulans, Bacillus subtilis, clostridium or Lactobacillus sporogenes · CPC title

• A61K35/747 Primary

  Lactobacilli, e.g. L. acidophilus or L. brevis · CPC title

• A61K9/19

  lyophilised {, i.e. freeze-dried, solutions or dispersions (lyophilised products with subsequent particle size reduction A61K9/14; granules or pellets made by lyphilisation A61K9/1682; solid oral dosage forms made by lyophilisation A61K9/2095; lyophilisation additives A61K47/00)} · CPC title

• A61K9/0053

  Mouth and digestive tract, i.e. intraoral and peroral administration · CPC title